Canadian Association for Porphyria

Porphyria Treatment

Special Access Programme (SAP) - Ontario

In Ontario, Normosang is available through the Special Access Program and is funded through the Inherited Metabolic Diseases Program. It is provided as follows:

Acute intermittent porphyria 

Note: Eligibility criteria for IMD program funding (all criteria must be met): 

1. Diagnosis of acute intermittent porphyria should be confirmed by biochemical and molecular testing, and; 

2. Hemin (Normosang) infusions should only be given under supervision and be prescribed by hematologists, gastroenterologists or metabolic specialists, and; 

3. For continued funding, yearly follow up report should be submitted to the IMD program by the prescribing physician.    

Ontario Inherited Metabolic Diseases (IMD) Program List of Disorders, Covered Drugs, Supplements and Specialty Foods.pdf



Source: Inherited Metabolic Diseases Program - Ontario Ministry of Health and Long-term Care

Last Updated: 10/January/2017 

Medical Disclaimer

Care has been taken to ensure that the information on this website is accurate at the time of publication. This information is, however, intended for general guidance only and is not meant to substitute consultation from a recognized health professional. The Canadian Association for Porphyria/Association Canadienne de Porphyrie disclaims for itself and for the author of this information, all responsibility for any mis-statements or for consequences of actions taken by any person while acting on information contained herein. Physicians and patients must make their own decisions about therapy according to the individual circumstances of each case.

Powered by Wild Apricot Membership Software